SynthesisEating and weight disorders : EWD2024
Eating disorders and disordered eating symptoms in individuals at clinical high risk for psychosis: a systematic review and meta-analysis.
Synthesis in Eating and weight disorders : EWD, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The association between disordered eating and psychosis in clinical and non-clinical populations: a systematic review and meta-analysis.Psychological medicine · 2025Pooled it
- Co-Occurrence of Avoidant/Restrictive Food Intake Disorder (ARFID) and Schizophrenia-Spectrum Disorders: A Comprehensive Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEating disorders (EDs) are among the least studied mental disorders in individuals at clinical high risk for psychosis (CHR-P). The primary aim (a) of this systematic review and meta-analysis was to identify factors predicting ED diagnoses in CHR-P individuals. The secondary aim (b) was providing a comprehensive clinical description of individuals with both CHR-P and EDs/ED-related symptoms.
methodsPreferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020-compliant systematic review and meta-analysis, searching PubMed/(EBSCO)PsycINFO/Web of Science for studies published between 01/01/2018 and 30/05/2023, including individuals with CHR-P and EDs/ED symptoms (PROSPERO CRD42023488792). Quality assessment was performed using the Newcastle-Ottawa Scale (NOS). We performed a meta-regression model on the proportion of EDs in CHR-P individuals (primary aim) and conducted a narrative synthesis (secondary aim).
resultsWe included 26 articles, reporting on 2,060 and 589 subjects for study aim (a) and (b), respectively (mean NOS score = 6.38). The prevalence of EDs in CHR-P individuals was 0.05 (95% CI 0.3-0.8). No factor had a significant effect on the proportion of EDs in CHR-P individuals. This result is limited by the inability to include ED-related symptoms and antipsychotic prescriptions in the meta-regression model, due to an insufficient number of studies reporting on these variables. The narrative synthesis offers a characterization of individuals with both CHR-P and ED/ED-related symptoms; however, the limited number of included studies is insufficient to support definitive conclusions.
conclusionsNo significant predictor of EDs was found in CHR-P individuals. Transdiagnostic, prospective cohort studies are warranted to examine long-term outcomes in individuals with both CHR-P and EDs, beyond diagnostic silos. LEVEL OF EVIDENCE: I. Systematic review and meta-analysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.